BWBendik Slagsvold Winsvold

Bendik Slagsvold Winsvold

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bendik Slagsvold Winsvold has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Foundation Model Forecasting of Headache Days in People With Persisting Postconcussion Symptoms

    by Antonios Danelakis, Gøril Storvig, Marte Helene Bjørk, Daniela Contreras, Manjit Matharu, Parashkev Nachev, Bendik Slagsvold Winsvold, Erling Tronvik, Anker Stubberud, Alexander Olsen

    Objectives: We aimed to forecast headache in individuals with persisting postconcussion symptoms using foundation machine learning (ML) models and multimodal longitudinal data. Methods: This was an ML analysis of data from the Digital Solutions for Concussion (DiSCo) study, a research project assessing the usability and feasibility of 2 mobile health apps for individuals with persisting postconcussion symptoms. The participants completed daily symptom registrations and daily biofeedback sessions measuring heart rate variability, peripheral skin temperature, and upper trapezius muscle tension. Two foundation ML models, TabPFN and longitudinal TabPFN, were recruited and evaluated to predict moderate-to-severe (at least 4 on the 11-point numeric rating scale) headache days occurring in the subsequent 24-hour window using prior physiological and symptom data. The top-performing model was further evaluated for forecasting days with fatigue, which was rated as the second to headache most bothersome symptom, within the subsequent 24-hour window. Models were trained and optimized on a train-set and evaluated on a hold-out test-set with the area under the receiver operating characteristics curve (AUC) and 95% confidence intervals (CIs). Results: Twenty individuals were included in the forecasting models, with data collected over a planned 28-day registration period, yielding a total of 338 days. The most stable model, longitudinal TabPFN, achieved a test-set AUC of 0.69 (95% CI: 0.62–0.74). The conventional TabPFN model achieved an AUC of 0.68 (95% CI: 0.55–0.80). In the case of fatigue, the longitudinal TabPFN model achieved an AUC of 0.81 (95% CI: 0.75–0.86). Both physiological measurements and symptomology information seemed to be important predictors. Conclusions: Moderate-to-severe postconcussion headache days can be predicted with modest accuracy 24 hours before their occurrence from multimodal physiological and self-reported symptomatology data. Incorporating temporal dynamics using longitudinal foundation models may improve such forecasting.

  • Open Access

    Genome-wide association analyses of borderline personality disorder identify 11 loci and highlight shared risk with mental and somatic disorders

    by Fabian Streit, Swapnil Awasthi, Alisha S. M. Hall, Alice Braun, Maria Niarchou, Eirini Marouli, Oladapo Babajide, Josef Frank, Lea Zillich, Carolin M. Callies, et al.

    Borderline personality disorder (BPD) is a severe mental health condition influenced by environmental risk factors (for example, interpersonal trauma) and genetic factors. We conducted the largest genome-wide association study (GWAS) meta-analysis of BPD so far, with a discovery sample of 12,339 cases and 1,041,717 controls, and a replication study of 685 cases and 107,750 controls (all participants of European ancestry). We identified 11 independent associated genomic loci and 9 risk genes in gene-based analyses. We observed a single-nucleotide polymorphism heritability of 17.3% and derived polygenic scores (PGS) that predicted 4.6% of the phenotypic variance in BPD on the liability scale. BPD showed the strongest positive genetic correlations with GWAS of post-traumatic stress disorder, depression, attention deficit hyperactivity disorder, antisocial behavior, and measures of suicide and self-harm. Phenome-wide analyses in Vanderbilt University Medical Center Biobank and UK Biobank using BPD-PGS confirmed these associations and also identified associations with other medical conditions, including obstructive pulmonary disease and diabetes. These analyses highlight BPD as a polygenic disorder, with the genetic risk showing substantial overlap with psychiatric and physical health conditions.


  • Open Access

    Prediction of migraine treatment response with clinical and genetic data: A machine learning analysis of the HUNT study.

    by Håkon Kvisle Abildsnes, Antonios Danelakis, Samita Giri, Dominic Giles, Manjit Matharu, Parashkev Nachev, Marte Helene Bjørk, Bendik S Winsvold, Knut Hagen, Sigrid Børte, et al.

    Migraine is highly heritable, yet no machine learning models for predicting treatment responses have incorporated genetic data. We aimed to develop machine learning models including both genetic and clinical information to predict treatment responses of migraine preventives and treatment retention of triptans. This was a cross-sectional population-based machine learning analysis of the Trøndelag Health Studies and the national prescription registry. Clinical predictors included demographics, serum metabolic measures, comorbidities, mental health and lifestyle factors. Genetic predictors included 108 migraine risk loci. Preventive response was defined as ≥50% reduction in triptan dispensations after first preventive dispensation, and triptan retention as ≥3 dispensations. The dataset was split into training (70%), validation (10%) and test set (20%). A series of standard and causal machine learning architectures were trained and optimized on the training and validation set, and the best model was evaluated on the held-out test data. Shapley Additive exPlanation values identified key predictors. In total, 475 participants tried a preventive (amitriptyline, beta-blocker, candesartan or topiramate) and 565 a triptan (371 sumatriptan) during the project period. Using only clinical features, the best models achieved area under curve of 0.56-0.69 for the preventives, and 0.56 for triptans. When combining clinical and genetic data, the area under curve was unchanged or reduced in all cases except for amitriptyline (0.80) and sumatriptan (0.55). The most important predictors were hormone-related features, lipid levels and hemodynamic parameters. We developed models that predicted treatment responses to amitriptyline, beta-blockers, candesartan and topiramate with modest accuracy. Incorporating genetic data did not enhance performance, although the limited sample size and the uncertain accuracy of cohort definition and treatment response assessment prevent firm conclusions.

  • Top Cited Papers
    Open Access

    Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling

    by Nora I. Strom, Brad Verhulst, Silviu-Alin Bacanu, Rosa Cheesman, Kirstin L. Purves, Hüseyin Gedik, Brittany L. Mitchell, Alex S. Kwong, Annika B. Faucon, Kritika Singh, et al.

    The major anxiety disorders (ANX; including generalized anxiety disorder, panic disorder and phobias) are highly prevalent, often onset early and cause substantial global disability. Although distinct in their clinical presentations, they probably represent differential expressions of a dysregulated threat–response system. Here, we present a genome-wide association meta-analysis comprising 122,341 European ancestry ANX cases and 729,881 controls. We identified 58 independent genome-wide significant risk variants and 66 genes with robust biological support. In an independent sample of 1,175,012 self-report ANX cases and 1,956,379 controls, 51 out of the 58 associations replicated. As predicted by twin studies, we found substantial genetic correlation between ANX and depression, neuroticism and other internalizing phenotypes. Follow-up analyses demonstrated enrichment in all major brain regions and highlighted GABAergic signaling as one potential mechanism implicated in ANX genetic risk. These results advance our understanding of the genetic architecture of ANX and prioritize genes for functional follow-up studies.


  • Open Access

    The burden of high-frequency episodic migraine and chronic migraine in the population-based PopHEAD study

    by Helene Engstrand, Maria Bengtson Argren, John-Anker Zwart, Erling Tronvik, Bendik Slagsvold Winsvold

    Aim: The diagnostic criteria for chronic migraine, which are based on the total number of monthly headache days, are the subject of ongoing debate. The present study aimed to investigate and compare the burden of disease and quality of life between high-frequency episodic migraine and chronic migraine, using data from the large population-based PopHEAD study. Methods: PopHEAD is a population-based cross-sectional study in the Norwegian county of Vestfold and Telemark performed in 2023. Among 28,753 randomly selected adults (aged 18–70 years) invited to complete an electronic questionnaire, 8265 (28.7%) participants responded. The questionnaire was a modified version of the Headache-Attributed Restriction, Disability, Social Handicap and Impaired Participation questionnaire, and migraine was classified using a diagnostic algorithm that has been validated by telephone interview in this population. High-frequency episodic migraine was classified according to newly proposed criteria, and chronic migraine according to International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria. Using linear regression for continuous variables and logistic regression for binary outcomes, we compared the disease burden and quality of life between participants classified with high-frequency episodic migraine and those with chronic migraine. The analysis was conducted in two steps: a primary analysis adjusted for age and sex, as well as a second analysis with an additional adjustment for monthly migraine days. Results: Of the 8265 responders, 225 had high-frequency episodic migraine and 349 had chronic migraine. Compared to the high-frequency episodic migraine group, the chronic migraine group had more monthly migraine days (17.9 vs. 9.7, p < 0.001) and headache days (20.8 vs. 9.9, p < 0.001). The chronic migraine group also used more acute medication ( p < 0.001). In analyses adjusted for age and sex, participants with chronic migraine reported greater disease burden across almost all measures, including work and social impairment, and had a lower quality of life ( p < 0.01). With additional adjustment for monthly migraine days, no significant differences in disease burden were found between the two groups, except from days missed from household work ( p = 0.03). Conclusions: The higher disease burden observed in chronic migraine compared to high-frequency episodic migraine was fully explained by the higher number of monthly migraine days in the chronic migraine group. Our findings support previous suggestions to simplify the ICHD-3 criteria for chronic migraine by basing it solely on the number of monthly migraine days.


  • Genome-wide association study of neuropathic pain

    by Mari Spildrejorde, Øystein Dunker, Sara Maria Allen, Marie Bu Kvaløy, Martin Uglem, Ina Hjelland, Sissel Løseth, David L. Bennett, John-Anker Zwart, Bendik S. Winsvold, et al.

    Neuropathic pain is a complex chronic condition with a multifactorial etiology that includes genetic susceptibility. However, the genetic basis of neuropathic pain remains poorly understood. We aimed to investigate genetic variants associated with the presence and intensity of neuropathic pain using genome-wide association analyses in the GeNeuP cohort, comprised of 1146 deeply phenotyped individuals with peripheral neuropathy from Norway. Genotyping was performed using the Illumina Global Screening Array, and analyses were conducted to test associations with the presence and intensity of neuropathic pain. No significant associations were detected at the genome-wide significance level ( P < 5 × 10 −8 ) for either the presence or intensity of neuropathic pain. However, at the subthreshold level ( P < 10 −6 ), 3 single nucleotide polymorphisms (annotated to the CHRDL1 and MCF2L gene and a long non-coding RNA) were associated with intensity of neuropathic pain. A targeted candidate gene analysis of 163 genes previously implicated in neuropathic pain and neuropathy did not yield significant associations. These results highlight the complexity of the genetic architecture underlying neuropathic pain and the challenges in identifying common variants with detectable effects. The identification of subthreshold associations of genes involved in synaptic plasticity is intriguing and merits further investigation. Larger studies with refined phenotyping will be essential to validate these signals and to advance understanding of the genetic contributors to neuropathic pain.


  • Top Cited Papers
    Open Access

    Genome-wide analyses identify 30 loci associated with obsessive–compulsive disorder

    by Nora I. Strom, Zachary F. Gerring, Marco Galimberti, Dongmei Yu, Matthew W. Halvorsen, Abdel Abdellaoui, Cristina Rodriguez-Fontenla, Julia M. Sealock, Tim Bigdeli, Jonathan R. Coleman, et al.

    Obsessive–compulsive disorder (OCD) affects ~1% of children and adults and is partly caused by genetic factors. We conducted a genome-wide association study (GWAS) meta-analysis combining 53,660 OCD cases and 2,044,417 controls and identified 30 independent genome-wide significant loci. Gene-based approaches identified 249 potential effector genes for OCD, with 25 of these classified as the most likely causal candidates, including WDR6, DALRD3 and CTNND1 and multiple genes in the major histocompatibility complex (MHC) region. We estimated that ~11,500 genetic variants explained 90% of OCD genetic heritability. OCD genetic risk was associated with excitatory neurons in the hippocampus and the cortex, along with D1 and D2 type dopamine receptor-containing medium spiny neurons. OCD genetic risk was shared with 65 of 112 additional phenotypes, including all the psychiatric disorders we examined. In particular, OCD shared genetic risk with anxiety, depression, anorexia nervosa and Tourette syndrome and was negatively associated with inflammatory bowel diseases, educational attainment and body mass index.


  • Top Cited Papers
    Open Access

    Translational genomics of osteoarthritis in 1,962,069 individuals

    by Konstantinos Hatzikotoulas, Lorraine Southam, Lilja Stefansdottir, Cindy G. Boer, Merry-Lynn McDonald, J. Patrick Pett, Young-Chan Park, Margo Tuerlings, Rick Mulders, Andrei Barysenka, et al.

    Osteoarthritis is the third most rapidly growing health condition associated with disability, after dementia and diabetes1. By 2050, the total number of patients with osteoarthritis is estimated to reach 1 billion worldwide2. As no disease-modifying treatments exist for osteoarthritis, a better understanding of disease aetiopathology is urgently needed. Here we perform a genome-wide association study meta-analyses across up to 489,975 cases and 1,472,094 controls, establishing 962 independent associations, 513 of which have not been previously reported. Using single-cell multiomics data, we identify signal enrichment in embryonic skeletal development pathways. We integrate orthogonal lines of evidence, including transcriptome, proteome and epigenome profiles of primary joint tissues, and implicate 700 effector genes. Within these, we find rare coding-variant burden associations with effect sizes that are consistently higher than common frequency variant associations. We highlight eight biological processes in which we find convergent involvement of multiple effector genes, including the circadian clock, glial-cell-related processes and pathways with an established role in osteoarthritis (TGFβ, FGF, WNT, BMP and retinoic acid signalling, and extracellular matrix organization). We find that 10% of the effector genes express a protein that is the target of approved drugs, offering repurposing opportunities, which can accelerate translation.


  • Open Access

    Genome-wide association study of borderline personality disorder identifies 11 loci and highlights shared risk with mental and somatic disorders

    by Fabian Streit, Swapnil Awasthi, Alisha Sm Hall, Alice Braun, Maria Niarchou, Eirini Marouli, Oladapo Babajide, Josef Frank, Lea Zillich, Carolin M Callies, et al.

    We conducted the largest genome-wide meta-analysis of borderline personality disorder (BPD) to date, with a discovery sample of 12,339 cases and 1,041,717 controls, and a replication study of 685 cases and 107,750 controls (all participants of European ancestry). We identified 11 independent associated genomic loci, and nine risk genes in the gene-based analysis. We observed a single-nucleotide polymorphism (SNP) heritability of 17.3% and derived polygenic scores (PGS) predicted 4.6% of the phenotypic variance in BPD on the liability scale. BPD showed the strongest positive genetic correlations with GWAS of posttraumatic stress disorder, depression, attention deficit hyperactivity disorder, antisocial behavior, and measures of suicide and self-harm. Phenome-wide association analyses using BPD-PGS confirmed these associations and additionally revealed associations with general medical conditions including obstructive pulmonary disease and diabetes. The present analyses highlight BPD as a polygenic disorder, with the genetic risk showing substantial overlap with psychiatric and physical health conditions.


  • Open Access

    Relationship between migraine and epilepsy in a large population‐based cohort: The HUNT Study

    by Helene Engstrand, Eline Revdal, Maria Bengtson Argren, Knut Hagen, John‐Anker Zwart, Eylert Brodtkorb, Bendik Slagsvold Winsvold

    Background and Purpose: Several studies have reported substantial comorbidity between epilepsy and migraine. Most of these were based on clinical cohorts or used unvalidated diagnostic instruments. Our study re‐examined this association in a large general population cohort using validated diagnoses for both disorders.Methods: A total of 65,407 participants (≥20 years old) from HUNT (the Trøndelag Health Study) were classified for migraine and nonmigraine headache using a validated questionnaire. Medical record review was used to validate and classify epilepsy in 364 participants (cases), who were compared with 63,298 participants without epilepsy (controls). The association between epilepsy and migraine was analysed using logistic regression adjusted for sex and age.Results: Patients with epilepsy had no increased prevalence of migraine (odds ratio [OR] = 0.95, 95% confidence interval [CI] = 0.68–1.33) or nonmigraine headache (OR = 1.18, 95% CI = 0.93–1.50) compared to controls. When stratified by headache frequency, epilepsy was associated with a higher prevalence of migraine with highly frequent headache (≥7 days/month; OR = 1.73, 95% CI = 1.08–2.78).Conclusions: Migraine was equally common in people with and without epilepsy. Patients with epilepsy who suffered from migraine were more prone to having highly frequent migraine.